{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T17:41:12Z","timestamp":1648748472285},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00120-021-01681-8","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T11:03:30Z","timestamp":1635419010000},"page":"1400-1408","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bacillus Calmette-Gu\u00e9rin (BCG) und Alternativen"],"prefix":"10.1007","volume":"60","author":[{"given":"K.","family":"Leucht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Foller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Oliver","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"1681_CR1","volume-title":"EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS)","author":"M Babjuk","year":"2021","unstructured":"Babjuk\u00a0M et al (2021) EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS)"},{"issue":"7","key":"1681_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar\u00a0AV et al (2021) Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 22(7):919\u2013930","journal-title":"Lancet Oncol"},{"key":"1681_CR3","unstructured":"iMedikament.de (2010) BCG-Medac, Fachinformation. https:\/\/imedikament.de\/bcg-medac\/fachinformation. Zugegriffen: 19. Aug. 2021"},{"issue":"4","key":"1681_CR4","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","volume":"63","author":"A B\u00f6hle","year":"2004","unstructured":"B\u00f6hle\u00a0A, Bock\u00a0PR (2004) Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63(4):682\u2013686 (discussion 686\u2013687)","journal-title":"Urology"},{"issue":"1","key":"1681_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian\u00a0SA et al (2021) Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a\u00a0single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 22(1):107\u2013117","journal-title":"Lancet Oncol"},{"issue":"4","key":"1681_CR6","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/j.eururo.2020.07.004","volume":"78","author":"MO Grimm","year":"2020","unstructured":"Grimm\u00a0MO, Caris\u00a0C, Witjes\u00a0WPJ (2020) Reply to Emre Karabay and \u0130lker T\u0131nay\u2019s letter to the editor Re: Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology research foundation randomised phase III clinical trial \u201eNIMBUS\u201c. Eur Urol. im Druck. https:\/\/doi.org\/10.1016\/j.eururo.2020.04.066. Eur Urol 78(4):e163\u2013e164","journal-title":"Eur Urol"},{"issue":"5","key":"1681_CR7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"MO Grimm","year":"2020","unstructured":"Grimm\u00a0MO et al (2020) Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology research foundation randomised phase III clinical trial \u201eNIMBUS\u201c. Eur Urol 78(5):690\u2013698","journal-title":"Eur Urol"},{"issue":"3","key":"1681_CR8","doi-asserted-by":"publisher","first-page":"108.e1","DOI":"10.1016\/j.urolonc.2014.02.020","volume":"33","author":"HW Herr","year":"2015","unstructured":"Herr\u00a0HW, Milan\u00a0TN, Dalbagni\u00a0G (2015) BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a\u00a0prospective cohort outcomes study. Urol Oncol 33(3):108.e1\u2013108.e4","journal-title":"Urol Oncol"},{"issue":"16","key":"1681_CR9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat\u00a0AM et al (2016) Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J\u00a0Clin Oncol 34(16):1935\u20131944","journal-title":"J Clin Oncol"},{"issue":"4","key":"1681_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm\u00a0DL et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a\u00a0randomized Southwest Oncology Group Study. J\u00a0Urol 163(4):1124\u20131129","journal-title":"J Urol"},{"key":"1681_CR11","volume-title":"S3-Leitlinie Harnblasenkarzinom, Version 2.0","author":"Leitlinienprogramm Onkologie","year":"2020","unstructured":"Leitlinienprogramm Onkologie (2020) S3-Leitlinie Harnblasenkarzinom, Version 2.0"},{"issue":"2","key":"1681_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m\u00a0PU et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247\u2013256","journal-title":"Eur Urol"},{"issue":"2","key":"1681_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","volume":"68","author":"L Mart\u00ednez-Pi\u00f1eiro","year":"2015","unstructured":"Mart\u00ednez-Pi\u00f1eiro\u00a0L et al (2015) Maintenance therapy with 3\u2011monthly bacillus Calmette-Gu\u00e9rin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013. Eur Urol 68(2):256\u2013262","journal-title":"Eur Urol"},{"issue":"2","key":"1681_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales\u00a0A, Eidinger\u00a0D, Bruce\u00a0AW (1976) Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J\u00a0Urol 116(2):180\u2013183","journal-title":"J Urol"},{"issue":"3","key":"1681_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens\u00a0J et al (2013) Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1\u00a0year versus 3\u00a0years of maintenance. Eur Urol 63(3):462\u2013472","journal-title":"Eur Urol"},{"issue":"2","key":"1681_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.juro.2013.08.022","volume":"191","author":"JP Sfakianos","year":"2014","unstructured":"Sfakianos\u00a0JP, Kim\u00a0PH, Hakimi\u00a0AA, Herr\u00a0HW (2014) The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Gu\u00e9rin. J\u00a0Urol 191(2):341\u2013345","journal-title":"J Urol"},{"key":"1681_CR17","first-page":"CD006885","volume":"5","author":"PF Shang","year":"2011","unstructured":"Shang\u00a0PF et al (2011) Intravesical bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev 5:CD6885","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1681_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester\u00a0RJ et al (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3\u00a0study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Gu\u00e9rin, and bacillus Calmette-Gu\u00e9rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57(5):766\u2013773","journal-title":"Eur Urol"},{"issue":"5","key":"1681_CR19","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester\u00a0RJ, van der Meijden\u00a0AP, Lamm\u00a0DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J\u00a0Urol 168(5):1964\u20131970","journal-title":"J Urol"},{"issue":"3","key":"1681_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester\u00a0RJ et\u00a0al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a\u00a0combined analysis of 2596\u00a0patients from seven EORTC trials. Eur Urol 49(3):466\u2013475 (discussion 475\u2013477)","journal-title":"Eur Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01681-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-021-01681-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01681-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T11:38:30Z","timestamp":1636025910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-021-01681-8"}},"subtitle":["Medikament\u00f6se Therapie des \u201ehigh-risk\u201c nicht-muskelinvasiven Blasenkarzinoms"],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1681"],"URL":"https:\/\/doi.org\/10.1007\/s00120-021-01681-8","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"assertion":[{"value":"16 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Leucht gibt an: Scientific Writing: Bristol Myers Squibb; au\u00dferhalb der eingereichten Arbeit. S.\u00a0Foller gibt an: Referentenhonorar oder Erstattung von Kongresskosten: Astra Zeneca, Bristol Myers Squibb, Ipsen, MSD, Merck, Pfizer; Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger: Astra Zeneca, MSD, Merck, Pfizer; au\u00dferhalb der eingereichten Arbeit. M.-O.\u00a0Grimm gibt an: Forschungsf\u00f6rderung oder geldwerte Leistungen: Bristol Myers Squibb, Intuitive Surgical; Referentenhonorar oder Erstattung von Kongresskosten: Apogepha, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Hexal, Ipsen, Medac, Merck Serono, MSD, Novartis, ONO Pharma, Pfizer; Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger: Amgen, Apogepha, AstraZeneca, Bayer, Bristol Myers Squibb, ClinSol, Eisai, EUSA Pharma, Hexal, Intuitive Surgical, Ipsen, Janssen, Merck Serono, MSD, Novartis, ONO Pharma, Pfizer, Roche, Sanofi, Takeda; au\u00dferhalb der eingereichten Arbeit.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}